Amedisys (AMED) Tops Q1 EPS by 11c; Offers FY22 Guidance

Amedisys (NASDAQ: AMED) reported Q1 EPS of $1.23, $0.11 better than the analyst estimate of $1.12. Revenue for the quarter came in at $545.3 million versus the consensus estimate of $558.84 million.

GUIDANCE:

Amedisys sees FY2022 EPS of $5.23-$5.45, versus the consensus of $5.33. Amedisys sees FY2022 revenue of $2.33-2.365 billion, versus the consensus of $2.36 billion.

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• United Natural Foods (UNFI) Reports In-Line Q3 EPS ; Offers Outlook
• MIND Technology (MIND) Misses Q1 EPS by 5c